Thomas Gajewski, MD, PhD
Enriched profileAbbVie Foundation Professor of Pathology; Professor of Medicine; Professor, Ben May Department for Cancer Research; Leader, Immunology and Cancer Program, University of Chicago Comprehensive Cancer Center · University of Chicago
Thomas Gajewski is AbbVie Foundation Professor of Pathology; Professor of Medicine; Professor, Ben May Department for Cancer Research; Leader, Immunology and Cancer Program, University of Chicago Comprehensive Cancer Center at University of Chicago. ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 22 Oct 2026
Thomas F. Gajewski is AbbVie Foundation Professor of Pathology at University of Chicago. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 11 companies, 15 NIH-funded awards (1998–2026).
- Top research focus: Melanoma
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 22 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 22 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
Sponsor: University of Chicago
- Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
Sponsor: National Cancer Institute (NCI)
- Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 22 Oct 2026
11 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20241 payment
- Merck Sharp & Dohme LLCProgram year20241 payment
- ABBVIE INC.Program year20239 payments$14,818openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
51.2%l-Thyroxine51.2%Levothyroxine Sodium100%Part D<11 patientsCancer & immunology
31.7%B-Raf serine-threonine kinase (BRAF) inhibitors15.9%Braftovi100%Part D<11 patientsMitogen-activated protein kinase (MEK) inhibitors15.9%Mektovi100%Part D<11 patientsSensory organs
17.1%Corticosteroid17.1%Hydrocortisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 22 Oct 2026
15 NIH research awards on record, funded 1998–2026 per NIH RePORTER. The latest:
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Online presence
Updated 22 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/thomas-gajewski-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/thomas-gajewski-40b00526
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
sitcancer.org/membership/academy-immuno-oncology/faio/gajewski-faio
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sitcancer.org ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/university-of-chicago-medicine-comprehensive-cancer-center_congrats-to-thomas-gajewski-md-phd-on-activity-7387163139366326272-qjaH
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/posts/university-of-chicago-medicine_congratulations-to-thomas-gajewski-md-phd-activity-6608792015868084224-qEjj
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/UCCancerCenter/status/1981412561527464374
- LinkedIn
LinkedIn profile (University of Chicago), auth-walled, not independently verified beyond listing
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 22 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- MD
University of Chicago Pritzker School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗ - PhD in Immunology
University of Chicago
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗ - AB/BS
University of Chicago
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →news.uchicago.edu ↗
Editorial & leadership roles
journal and society appointments- Immediate Past President
Society for Immunotherapy of Cancer (SITC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pathology.uchicago.edu ↗ - Founding Editor
Journal for Immunotherapy of Cancer (JITC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →brightpeaktx.com ↗ - Editor
Cancer Research (AACR journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uchicagomedicine.org ↗ - Past Chair
Cancer Immunopathology and Immunotherapy (CII) NIH grant review study section
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →brightpeaktx.com ↗ - Program committee service
ASCO and AACR
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pathology.uchicago.edu ↗ - Member
AACR Cancer Immunology Working Group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerresearch.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →brightpeaktx.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →brightpeaktx.com ↗
- Distinguished Professor designation
University of Chicago
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →brightpeaktx.com ↗
Secondary affiliations
appointments beyond the home institution- Committee on Cancer Biology
University of Chicago
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerbio.uchicago.edu ↗ - Committee on Immunology
University of Chicago
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →immunology.uchicago.edu ↗ - Director
Human Immunologic Monitoring core facility, University of Chicago
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pathology.uchicago.edu ↗ - Steering Committee member
Microbiome Medicine Program, University of Chicago
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mmp.bsd.uchicago.edu ↗ - Scientific/clinical advisor
Zai Laboratory
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →zailaboratory.com ↗ - Scientific advisor
Bright Peak Therapeutics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →brightpeaktx.com ↗ - Scientific advisor
Catalym
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →catalym.com ↗ - Affiliate scientist
Ludwig Cancer Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ludwigcancerresearch.org ↗
Media & interviews
press, podcasts and appearances- PBS "Great Conversations" (Season 20, Episode 7)
interview with Charles Graeber on cancer immunotherapy
- Moffitt Cancer Center "ImmunoVerse" podcast
"Hot vs. Cold Tumors: Decoding the Tumor Microenvironment"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - CancerNetwork video interview
"Analyzing the Tumor Microenvironment to Guide Immunotherapy in Melanoma"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- VJOncology speaker profile
multiple video interviews on melanoma immuno-oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Everett Vokes, MD
University of Chicago
Ralph Weichselbaum, MD
University of Chicago
Mary Rinella, MD
University of Chicago
Hedy Kindler, MD
University of Chicago
Jedd Wolchok, MD
Weill Cornell Medicine
Frank Hodi, MD
Dana-Farber Cancer Institute
Mario Sznol, MD
University of Miami Miller School of Medicine
Igor Puzanov, MD
Roswell Park Comprehensive Cancer Center